Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Adagene Inc.NASDAQ: ADAG

Gross Margin · Q4 FY2025 · quarter ended Dec 2025

Gross margin widens to 96.3%

Gross margin was 96.3% in Q4 FY2025, up 893.8 pp from a year earlier. On a trailing-twelve-month basis it was -14.6%, down 141.0 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
96.3%— QoQ
Last fiscal yearDec 2025
100.0%+897.5 pp YoY
LTMJun 2024
-14.6%-141.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+893.8 pp——
1 year+897.5 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+897.5pp

Gross Margin vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 gross margin of -14.6% is the lowest of the 5 companies compared; the peer median is 50.8%.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of -8.3 pp.
ADAG Competitors Peer median
Gross Margin for ADAG and competitors
Company Period LTM level YoY 3-year change
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
NTRBNutriband Inc.LTM Apr 202628.4% -4.9 pp-8.3 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
XBITXBiotech Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding ADAG) 50.8%-4.9 pp-8.3 pp

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.18M9.29M18.11M103.2K7.67M
Cost of Revenue00000
Gross Profit10.18M9.29M18.11M(823.04K)7.67M
Gross Margin100.0%100.0%100.0%-797.5%100.0%
Research & Development68.1M81.34M36.64M28.78M22.03M
Selling, General & Admin14.44M11.87M8.67M7.27M7.08M
Operating Expenses82.54M93.21M41.83M36.05M29.11M
Depreciation & Amortization1.13M1.43M1.21M926.25K589.79K
EBITDA(69.99M)(77.39M)(14.95M)(31.66M)(16.85M)
EBITDA Margin-687.8%-832.8%-82.5%-30680.5%-219.7%
Operating Income(72.36M)(83.92M)(23.72M)(35.95M)(21.44M)
Operating Margin-711.2%-903.1%-131.0%-34835.4%-279.5%
Interest Income76.17K377.5K4.28M3.8M2.3M
Interest Expense363.76K693.32K1.11M851.87K463.13K
Other Income / Expenses887.77K4.41M6.46M2.51M3.53M
Income Before Tax(71.48M)(79.51M)(17.25M)(33.44M)(17.91M)
Pre-Tax Margin-702.5%-855.6%-95.3%-32403.5%-233.4%
Income Tax Expense1.7M459.06K1.69M(17.55K)(297.86K)
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Net Margin-719.2%-860.6%-104.6%-32386.4%-229.6%
EPS (Basic)(2.29)(2.31)(0.55)(0.95)(0.46)
EPS (Diluted)(2.29)(2.31)(0.54)(0.95)(0.46)
Weighted Avg Shares32.02M34.65M34.64M36.02M37.76M
Weighted Avg Shares (Diluted)32.02M34.65M35.03M36.02M37.76M

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.